![conference banner](/images/conference-banner.jpeg)
Abstract
Dopamine is the predominant physiological inhibitory factor of prolactin release. Hyperprolactinemia is associated with potentially serious short and long-term clinical consequences. Several physiological and pathological conditions can cause elevated serum prolactin levels. Of these, in the psychiatric population, antipsychotic drugs are the most common. Because treatment of psychiatric illness often begins during adolescence and involves the long-term administration of these medications, the antipsychotic-induced hyperprolactinemia appears to be a major health concern for these patients. There are many possible management strategies of antipsychotic-induced hyperprolactinemia: estrogen/testosterone replacement, adding a dopamine agonist and introducing an alternative antipsychotic. Aripiprazole, a drug with partial agonist activity at dopamine D2 receptors, may be effective for antipsychotic-induced hyperprolactinemia. This paper reviews recent patents, mechanisms and evidences regarding the clinical action of aripiprazole on antipsychotic-induced hyperprolactinemia.
Keywords: Prolactin, hyperprolactinaemia, antipsychotics, aripiprazole, dopamine, partial agonism.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title:Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Volume: 4 Issue: 3
Author(s): Domenico De Berardis, Tiziano Acciavatti, Daniela Campanella, Nicola Serroni, Luigi Olivieri, Carla Ranalli, Viviana Marasco, Alessandro Carano, Marilde Cavuto, Giuseppe Di Iorio, Monica Piersanti, Francesco S. Moschetta and Massimo Di Giannantonio
Affiliation:
Keywords: Prolactin, hyperprolactinaemia, antipsychotics, aripiprazole, dopamine, partial agonism.
Abstract: Dopamine is the predominant physiological inhibitory factor of prolactin release. Hyperprolactinemia is associated with potentially serious short and long-term clinical consequences. Several physiological and pathological conditions can cause elevated serum prolactin levels. Of these, in the psychiatric population, antipsychotic drugs are the most common. Because treatment of psychiatric illness often begins during adolescence and involves the long-term administration of these medications, the antipsychotic-induced hyperprolactinemia appears to be a major health concern for these patients. There are many possible management strategies of antipsychotic-induced hyperprolactinemia: estrogen/testosterone replacement, adding a dopamine agonist and introducing an alternative antipsychotic. Aripiprazole, a drug with partial agonist activity at dopamine D2 receptors, may be effective for antipsychotic-induced hyperprolactinemia. This paper reviews recent patents, mechanisms and evidences regarding the clinical action of aripiprazole on antipsychotic-induced hyperprolactinemia.
Export Options
About this article
Cite this article as:
De Berardis Domenico, Acciavatti Tiziano, Campanella Daniela, Serroni Nicola, Olivieri Luigi, Ranalli Carla, Marasco Viviana, Carano Alessandro, Cavuto Marilde, Di Iorio Giuseppe, Piersanti Monica, S. Moschetta Francesco and Di Giannantonio Massimo, Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2010; 4 (3) . https://dx.doi.org/10.2174/1872214811004030230
DOI https://dx.doi.org/10.2174/1872214811004030230 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews The Wider Considerations in Closing Chronic Disease Gaps – Focus on Heart Failure and Implementation
Current Cardiology Reviews Exploring the Mechanism of Buyang Huanwu Decoction Alleviating Restenosis by Regulating VSMC Phenotype Switching and Proliferation by Network Pharmacology and Molecular Docking
Current Computer-Aided Drug Design Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry Body Fat Distribution Contributes to Defining the Relationship between Insulin Resistance and Obesity in Human Diseases
Current Diabetes Reviews Aging and Oral Health: Effects in Hard and Soft Tissues
Current Pharmaceutical Design Plasminogen Activator Inhibitor-1
Current Medicinal Chemistry The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury
Current Pharmaceutical Biotechnology COVID-19 Mortality and the Cytokine Storm: An Added Value for APOE Genotyping
Coronaviruses Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews The Antiplatelet Drug Target in Atherosclerotic Diseases
Cardiovascular & Hematological Disorders-Drug Targets Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews